trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

The $6.9bn deal, funded in part by an equity placement of approximately $3.5bn, includes a sizeable $1.35bn upfront payment which reflects the fact that the ADC – trastuzumab deruxtecan ... DS-8201 is currently in phase 3 testing for HER2-positive

Latest news

Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
NICE relents on Kadcyla after Roche pricing negotiations

The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that
A new decade of disruption: meeting the biosimilar challgenge

High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction

More from news
Approximately 5 fully matching, plus 43 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). . ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Director – Healthcare PR: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director, Healthcare Marketing Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...